AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis.
Kim DG, Choi Y, Lee Y, Lim S, Kong J, Song J, Roh Y, Harmalkar DS, Lee K, Goo JI, Cho HY, Mushtaq AU, Lee J, Park SH, Kim D, Min BS, Lee KY, Jeon YH, Lee S, Lee K, Kim S.
Kim DG, et al. Among authors: choi y.
Nat Commun. 2022 May 11;13(1):2572. doi: 10.1038/s41467-022-30149-2.
Nat Commun. 2022.
PMID: 35546148
Free PMC article.